ACCESSIBILITY

24/7

Headlines

21:39

Full list of Israeli high-tech layoffs in 2026

21:36

Remitly cuts 110 jobs in Israel and closes R&D hub three years after $80 million Rewire acquisition

16:41

Rigas: "Energean needs more gas to compete, and to prevent a monopoly"

16:31

“When you raise walls around data, employees go around them”

Buzz

Most popular

Daily

Weekly

Israeli defense firms target Asia as Singapore Airshow opens amid regional arms race

Chinese fund: “The Chinese government has imposed a ban on any new investment in Israel”

Cyera employees to sell tens of millions in shares at $9 billion valuation

Israeli startup raises $6.2 million to turn social media video into intelligence

Medtronic to acquire Israeli AI cardiology firm CathWorks for $585 million, deal could reach $1 billion

More news

Teva

20 stories about Teva

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer

The generic drugmaker shed 67% of its market price over the last 12 months

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer

Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone

Teva Offloads Holdings in Australia’s Mesoblast

25.10.17|Dror Reich and Lilach Baumer

The stem-cell therapy company diluted Teva’s shares through a new offering in August

Teva Canada Probed by Ontario Government

23.10.17|Lilach Baumer

According to a report by Canadian newspaper Toronto Star the company is under investigation for alleged illegal rebates given to pharmacies to boost sales. A Teva spokesman said the company will cooperate fully with any investigation by the Ontario Ministry of Health.

Teva Submits Potential Moneymaker Migraine Drug for FDA Approval

18.10.17|Dror Reich and Lilach Baumer

Teva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17|Golan Hazani

Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer

A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer

Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug

Teva Sells Remaining Women's Health Assets

18.09.17|Lilach Baumer

After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal

Teva Negotiating Sale of Remaining Women's Health Assets, Report Says

14.09.17|Lilach Baumer

CVC Capital Partners is nearing a $800 million deal for Teva's remaining Women's Health business, Bloomberg reported Thursday

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman

Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board

Teva Sells IUD Business for $1.1 Billion

12.09.17|Lilach Baumer

Going forward, the company will focus on central nervous system and respiratory treatments, shedding its Women's Health and Oncology and Pain businesses

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich

Troubled drugmaker says new CEO must work to quickly regain its financial credibility

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld

The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated

Bidders Line Up for Teva’s Women Health Unit, Report Says

23.08.17|Dror Reich

Church & Dwight Co. and Cooper Companies Inc. join other bidders for troubled drugmaker assets, Bloomberg reported Tuesday

U.S. Congress to Investigate Rising Multiple Sclerosis Drug Prices

21.08.17|Dror Reich

Two Congressmen are looking into the rising MS drug prices of seven pharmaceutical companies

Cerberus, Advent Eye Teva's European Assets, Report Says

15.08.17|Calcalist

The private equity firms are taking an interest in Teva's European oncology and pain treatment assets, estimated at $700 million to 1$ billion, according to a Bloomberg report

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani

The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian

The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016

Teva’s Perfect Storm Sends Tel-Aviv Stock Exchange Down

06.08.17|Calcalist

Teva’s stock price dropped sharply on Thursday and Friday after the company released quarterly revenue and profits that fell short of analysts’ forecasts

Previous Articles More Articles